Addex Therapeutics (ADXN) Income towards Parent Company: 2022-2025
Historic Income towards Parent Company for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$892,296.
- Addex Therapeutics' Income towards Parent Company rose 44.61% to -$892,296 in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.7 million, marking a year-over-year decrease of 9.16%. This contributed to the annual value of $13.6 million for FY2024, which is 251.63% up from last year.
- As of Q2 2025, Addex Therapeutics' Income towards Parent Company stood at -$892,296, which was down 37.78% from -$647,610 recorded in Q1 2025.
- Over the past 5 years, Addex Therapeutics' Income towards Parent Company peaked at $6.6 million during Q4 2022, and registered a low of -$7.5 million during Q2 2022.
- In the last 3 years, Addex Therapeutics' Income towards Parent Company had a median value of -$952,337 in 2023 and averaged -$1.2 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first soared by 93.66% in 2023, then plummeted by 119.12% in 2024.
- Over the past 4 years, Addex Therapeutics' Income towards Parent Company (Quarterly) stood at $6.6 million in 2022, then tumbled by 115.36% to -$1.0 million in 2023, then crashed by 34.16% to -$1.4 million in 2024, then spiked by 44.61% to -$892,296 in 2025.
- Its Income towards Parent Company was -$892,296 in Q2 2025, compared to -$647,610 in Q1 2025 and -$1.4 million in Q4 2024.